Adhesive patch

US9333182B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9333182-B2
Application numberUS-201214241622-A
CountryUS
Kind codeB2
Filing dateAug 31, 2012
Priority dateAug 31, 2011
Publication dateMay 10, 2016
Grant dateMay 10, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided is an adhesive patch which has excellent rivastigmine storage stability and an increased skin permeability of rivastigmine to such an extent that the amount of percutaneous absorption required for treating Alzheimer's disease is obtained. This adhesive patch includes a backing and an adhesive layer containing rivastigmine and an alkyl (meth)acrylate-based copolymer that does not contain any acrylic monomer component having a carboxy group, the adhesive layer being laid on one side of and integrated with the backing.

First claim

Opening claim text (preview).

The invention claimed is: 1. An adhesive patch comprising: a backing; and an adhesive layer containing rivastigmine and an alkyl (meth)acrylate-based copolymer without containing any acrylic monomer component having a carboxy group, the adhesive layer being laid on one side of and integrated with the backing, wherein the alkyl (meth)acrylate-based copolymer includes a copolymer containing a 2-ethylhexyl acrylate component, a 2-ethylhexyl methacrylate component and an alkyl (meth)acrylate component having an alkyl group with six or more carbon atoms except 2-ethylhexyl (meth)acrylate, wherein a total amount of the 2-ethylhexyl acrylate component and the 2-ethylhexyl methacrylate component is from 40 to 95% by weight of the copolymer, and an amount of the alkyl (meth)acrylate component having an alkyl group with six or more carbon atoms except 2-ethylhexyl (meth)acrylate is from 5 to 60% by weight of the copolymer. 2. The adhesive patch according to claim 1 , wherein the alkyl (meth)acrylate component has an alkyl group with 6 to 16 carbon atoms except 2-ethylhexyl (meth)acrylate. 3. The adhesive patch according to claim 1 , wherein the alkyl (meth)acrylate-based copolymer includes a 1-vinyl-2-pyrrolidone component. 4. The adhesive patch according to claim 1 , wherein the alkyl (meth)acrylate-based copolymer includes a copolymer (B) containing a 1-vinyl-2-pyrrolidone component and an alkyl acrylate component having an alkyl group with 1 to 12 carbon atoms. 5. The adhesive patch according to claim 1 , wherein rivastigmine is in a free base form. 6. The adhesive patch according to claim 1 , wherein the adhesive layer does not contain an antioxidant and a rivastigmine volatilization inhibitor.

Assignees

Inventors

Classifications

  • of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine · CPC title

  • for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

  • A61K9/7061Primary

    Polyacrylates · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9333182B2 cover?
Provided is an adhesive patch which has excellent rivastigmine storage stability and an increased skin permeability of rivastigmine to such an extent that the amount of percutaneous absorption required for treating Alzheimer's disease is obtained. This adhesive patch includes a backing and an adhesive layer containing rivastigmine and an alkyl (meth)acrylate-based copolymer that does not …
Who is the assignee on this patent?
Komoda Toshikazu, Sekisui Medical Co Ltd
What technology area does this patent fall under?
Primary CPC classification A61K9/7061. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue May 10 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).